In one paragraphArticle in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
Piotr RoszczenkoDepartment of Biotechnology, Medical University of Białystok, Kilińskiego 1, 15-089 Białystok, Poland.ORCID 0000-0001-9180-5901 Olga Klaudia Szewczyk-RoszczenkoDepartment of Synthesis and Technology of Drugs, Medical University of Białystok, Kilińskiego 1, 15-089 Białystok, Poland.ORCID 0000-0002-3719-6583 Agnieszka GornowiczDepartment of Biotechnology, Medical University of Białystok, Kilińskiego 1, 15-089 Białystok, Poland.ORCID 0000-0002-0945-7870 Robert CzarnomysyDepartment of Synthesis and Technology of Drugs, Medical University of Białystok, Kilińskiego 1, 15-089 Białystok, Poland.ORCID 0000-0002-7148-6111 Andrii LozynskyiDepartment of Pharmaceutical, Organic and Bioorganic Chemistry, Danylo Halytsky Lviv National Medical University, Pekarska 69, 79010 Lviv, Ukraine.ORCID 0000-0001-7151-2159 Krzysztof BielawskiDepartment of Synthesis and Technology of Drugs, Medical University of Białystok, Kilińskiego 1, 15-089 Białystok, Poland.ORCID 0000-0003-3187-4205 Roman LesykDepartment of Pharmaceutical, Organic and Bioorganic Chemistry, Danylo Halytsky Lviv National Medical University, Pekarska 69, 79010 Lviv, Ukraine.ORCID 0000-0002-3322-0080 Anna BielawskaDepartment of Biotechnology, Medical University of Białystok, Kilińskiego 1, 15-089 Białystok, Poland.
Funding
Medical University of Bialystok B.SUB.24.245Medical University of Bialystok B.SUB.24.366Medical University of Bialystok B.SUB.24.367Polish National Agency for Academic Exchange under the Strategic Partnerships programme grant agreement no. BPI/PST/2021/1/00002/U/00001
6 · The paper itselfAbstract
Gastric cancer remains a significant therapeutic challenge, highlighting the need for new strategies to improve treatment efficacy. This study investigates the potential of combined therapy with the novel Thiopyrano[2,3-
Indexed as
ApoptosisMembrane Potential, MitochondrialStomach NeoplasmsTrastuzumabAntineoplastic AgentsCell Line, TumorCell ProliferationCell SurvivalDrug SynergismHumansInterleukin-6ThiazolesTumor Suppressor Protein p53Antineoplastic AgentsInterleukin-6ThiazolesTrastuzumabTumor Suppressor Protein p534-thiazolidinoneanticanceranti-HER2combined therapygastric cancertrastuzumab
Identifiers
PMID39519758
PMCPMC11548019
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390